Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Ligand (LGND) Breakout! -- Ignore unavailable to you. Want to Upgrade?

To: Arthur Radley who wrote (9882)	10/21/1997 10:23:00 AM
From: Joe Wesley	Respond to of 32384

TD: If you ask BC they may e-mail you a copy (mschmitter@biocentury.com). They talk about all the things you have discussed one key may be a quote by D. Robinson "We wanted to partner with someone with a deep commitment to diabetes markets and, more importantly, to oral drugs, but with no conflicts with our programs,". They don't shed much light on the royalty situation other than saying lgnd would recieve double-digits for Targretin, LGD1324 and LGD1268 and other compounds selected as development candidates in the next 12 months. Amateur